Intellia Therapeutics (NTLA) Projected to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.32) per share and revenue of $8.10 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Intellia Therapeutics Stock Down 5.4 %

Shares of NASDAQ:NTLA opened at $11.51 on Tuesday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -2.12 and a beta of 1.80. Intellia Therapeutics has a 12-month low of $8.96 and a 12-month high of $34.87. The business’s 50 day moving average is $10.99 and its 200 day moving average is $15.87.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 29,000 shares of company stock valued at $352,551 in the last 90 days. Insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

NTLA has been the topic of several analyst reports. Barclays cut their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Chardan Capital lifted their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, November 18th. The Goldman Sachs Group cut their target price on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Wells Fargo & Company cut their target price on Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $56.00 to $11.00 in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $48.71.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.